Sponsor: NRG Oncology Foundation
Sponsor Study ID: NRG-HN014
Study Title: Randomized Phase III Trial of Neoadjuvant Immunotherapy with Response-Adapted Treatment Versus Standard-of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma
CTO #: 104173
NCT Number: NCT06568172
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Other Skin
Study Objectives: To determine if neoadjuvant immunotherapy combined with response-adapted oncologic surgery improves site-reported event-free survival (EFS) compared to standard-of-care surgery in resectable stage III/IV CSCC.